Navigation Links
New Podcast Sponsored by Asymmetrex Increases Awareness to the Need for Stem Cell Dose in Stem Cell Treatments
Date:11/6/2019

In October, Massachusetts stem cell biotechnology company Asymmetrex launched a new podcast to provide information to patients about a poorly disclosed deficiency in stem cell treatments. Throughout stem cell medical practice, stem cell treatments are given without knowing the dose of the treating stem cells. This problem affects all patients receiving stem cell treatments, including patients receiving approved treatments in routine clinical practice, patients volunteering for experimental treatments in FDA-authorized clinical trials, and patients obtaining unapproved treatments in private stem cell clinics.

The costs and dangers of unknown stem cell dose in treatments are significant. Stem cell clinical trials cannot be interpreted without knowing the treatment dose, leading to huge wastes of both federal and private clinical research dollars. In the case of manufactured stem cells, many treatments may contain very few or no stem cells at all. It is impossible for doctors to improve treatments without knowing the stem cell dose. Stem cell donors for approved treatments like blood stem cell transplantation are scarce. Knowing the stem cell dose would allow doctors to know when a treatment sample has enough stem cells to treat more than one patient; or when it does not have enough to treat even a single patient. In the second case, not knowing the stem cell dose can result in the death of children treated for leukemia when unknowingly they receive an umbilical cord blood transplant with too few blood stem cells to save them.

Earlier this year, the FDA recognized the pressing need for stem cell dose in stem cell medicine. The agency’s Standards Coordinating Body for Regenerative Medicine (SCB) listed stem cell dose determination as a priority for needed standards for stem cell medicine. Dose is a fundamental principle for the discovery, development, and administration of quality medicines. Asymmetrex Director James L. Sherley, M.D., Ph.D., who is featured in the new podcast, says that, “Dose is essential for stem cell medicine as well. The new podcast has the goal of informing the end users of stem cell treatments: the patients, their doctors, their families, and their advocates, including the FDA. When the people most impacted by these treatments understand that knowing the dose of stem cells is just as important as knowing the dose of their other medicines, they will be empowered to demand this essential certification of the integrity of their stem cell treatments.”

The first episode of the podcast, “Counting Stem Cells For A New Era Of Medicine,” aired online on October 17. The third episode of the biweekly, 6-episode series is scheduled for airing November 12. Each episode features an interview of Asymmetrex Director Sherley by podcast producer Jordan Rich. Mr. Rich guides Dr. Sherley through a discussion of questions that reveal the current challenges that Asymmetrex is addressing to achieve full adoption of stem cell dose as a routine practice in stem cell medicine. The series also highlights other significant applications for stem cell counting in drug development and environmental health science. In conjunction with this educational effort, the company is also sponsoring a study on its website to evaluate the current state of public, academic, and industry knowledge of coming changes in stem cell medicine related to the adoption of stem cell dose.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies and pre-clinical drug evaluations.

Read the full story at https://www.prweb.com/releases/new_podcast_sponsored_by_asymmetrex_increases_awareness_to_the_need_for_stem_cell_dose_in_stem_cell_treatments/prweb16701598.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Proactive Worldwide’s Travis Smith, Ph.D. Featured on Vanderbilt University’s Beyond the Lab Podcast
2. B&C Launches All Things Chemical™ Podcast
3. American Chemical Society podcast: Small dams create greenhouse gas hot spots
4. American Chemical Society podcast: Detecting radioactive material in nuclear waste water
5. American Chemical Society podcast: Improving disease monitoring in remote locations
6. American Chemical Society podcast: Cotton is an eco-friendly way to clean up oil spills
7. ACS podcast: Many people still lack access to flush toilets, adequate sanitation
8. CASIS-sponsored research heads to space station aboard SpaceX-3
9. Asymmetrex Approved to Conduct an ASTM Interlaboratory Evaluation of Its AlphaSTEM Test™ Technology as a Standard for Counting Therapeutic Adult Tissue Stem Cells
10. Asymmetrex Presents Proposal for ASTM Interlaboratory Evaluation of AlphaSTEM Test™ Technology Towards Establishing A Standard for Counting Therapeutic Stem Cells
11. Asymmetrex Publishes Chapter Explaining the Critical Need for Stem Cell Dosing for Success in Stem Cell Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2019)... ... November 21, 2019 , ... The inventors ... Center have announced a major step forward with that therapy, known as SurVaxM. ... the company, spun off from Roswell Park in 2012, has entered into a ...
(Date:11/19/2019)... ... November 19, 2019 , ... Project Lifeline – a community ... Foundation to address substance use disorder (SUD) – will take center stage ... led to the program’s effectiveness in preventing and treating opioid abuse in Blair County, ...
(Date:11/19/2019)... ... November 19, 2019 , ... The inaugural Cell & ... in New York City. The one-day event will be chaired by Dr Aiman Shalabi, ... in the space. , “We are witnessing significant innovation in cell and gene ...
Breaking Biology News(10 mins):
(Date:12/14/2019)... N.J. (PRWEB) , ... December 12, 2019 , ... ... manufacturer of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical ... launch of 2019. The new LDA LT80 (LOW TEMPERATURE -80C) helium leak testing ...
(Date:12/4/2019)... ... 03, 2019 , ... Absolute Antibody Ltd. , an ... the Recombinant Antibody Network (RAN), a consortium of three expert centers at the ... common goal to generate recombinant antibodies at a proteome-wide scale. Under the new ...
(Date:12/4/2019)... ... December 04, 2019 , ... Improved Pharma’s ... stabilize amorphous materials. Additionally, their PDF Synchrotron methods provide a way to determine ... compositions both in regulatory and patent applications.  , The latest developments were recently ...
(Date:11/27/2019)... ... 25, 2019 , ... Silony Medical, a medical technology company ... surgery in the UK. The procedure was performed in the UK’s largest trauma ... and Dr. Alexander Montgomery. The surgery, which took place on July 22, 2019, ...
Breaking Biology Technology: